Treatment failures for leishmaniasis with pentavalent antimonials, including meglumine antimonate, are increasingly common in many endemic areas. Imiquimod (Aldara; 3M Pharmaceuticals) is a novel immune response-activating compound, approved by the United States Food and Drug Administration, that is currently used to treat cervical warts and has been shown to activate macrophage killing of Leishmania species. Therefore, an open-label, prospective study was conducted of combined imiquimod plus meglumine antimonate therapy in 12 patients with cutaneous leishmaniasis who had previously not responded to meglumine antimonate therapy. All of the patients responded well to this combination therapy, and 90% were found to be cured at the 6-month follow-up period.
but they may last for years. They predispose affected people to secondary bacterial infections, often resulting in serious scarring [1, 2] .
The mainstay treatment for all forms of leishmaniasis is pentavalent antimony (Sb 5ϩ ) in the form of sodium stibogluconate (Pentostam; Burroughs Wellcome) or meglumine antimonate (Glucantime; Aventis Pasteur). Pentavalent antimonials have been used for therapy for leishmaniasis in humans since 1911 and are administered via the im or iv routes, typically at a dosage of 20 mg of Sb 5ϩ per kg of body weight per day for 20 days [2, 3] . Treatment with antimonials is often toxic, leading to damage of the heart, liver, pancreas, and hematopoietic tissues. Many patients experience malaise, nausea, headache, myalgia, arthralgia, and anorexia, and they may experience elevations in liver enzyme levels and changes visible on electrocardiographs [2, 3] .
Four Leishmania species have been described in Peru: Leishmania peruviana, Leishmania braziliensis, Leishmania guyanensis, and Leishmania mexicana, but only the first 2 have epidemiological importance. L. peruviana causes Andean cutaneous leishmaniasis (Uta), and L. braziliensis is the agent of mucocutaneous leish-maniasis (Espundia). In all forms of leishmaniasis, tissue macrophages are the primary cellular targets. Uta is endemic in the rural Andean and inter-Andean valleys between 1000 and 3000 m above sea level [4] . There is increasing evidence of clinical resistance to pentavalent drugs that contain antimony, with treatment failure rates of 120% [5] .
Imiquimod is a novel compound, (1-(2-methylpropyl)-1H-imidazo(4,5-c)quinolin-4-amine), that has been approved by the US Food and Drug Administration for topical use as a 5% cream (imiquimod [Aldara; 3M Pharmaceuticals]). Imiquimod exhibits antiviral activities in a number of in vitro and animal models [6] and is widely used clinically for the treatment of cutaneous genital warts caused by human papillomavirus infection [7] . Imiquimod acts against human papillomavirus infection as an immune response modifier through stimulating a local immune response at the site of application on the cutaneous genital wart, resulting in wart regression and resolution of infection. Furthermore, in peripheral blood mononuclear cells in humans, imiquimod is a potent inducer of cytokines, such as IFN-a, a variety of interleukins, and TNF [8] . We have shown elsewhere that imiquimod activates macrophages to release nitric oxide, thus killing intracellular Leishmania amastigotes in vitro, and imiquimod was also effective in the treatment of experimentally induced murine cutaneous leishmaniasis [9] . Through the use of gene array analysis, imiquimod and the related molecule S-28463 have been shown to activate a variety of genes associated with macrophage activation [10] .
On the basis of the above, we conducted an open-label, prospective study of combined meglumine antimonate plus imiquimod therapy in 12 patients with cutaneous leishmaniasis who had previously not responded to a complete course of meglumine antimonate therapy.
PATIENTS AND METHODS
Patient population. The study was conducted in 2 locations: Cayetano Heredia Hospital (Lima, Peru) and the rural health center of Churin (450 km from Lima, Peru, 2400 m above sea level) from January through October 2000. All of the patients were from regions where L. peruviana was endemic. The study was approved by the ethical committees of Universidad Peruana Cayetano Heredia (Lima, Peru) and McGill University (Montreal). Written informed consent to participate in the study was obtained from all patients. We included 12 patients with active lesions who had previously not responded to Peruvian Health Ministry standard treatment with systemic meglumine antimonate (20 mg of Sb 5ϩ per kg of body weight per day, delivered intravenously or intramuscularly for 20 days).
Patients aged у1 year with no evidence of mucosal involvement were eligible for the study. All patients had responded to у1 standard treatment course with meglumine antimonate.
"Lack of response to therapy" was classified as no reduction in the size of the lesion, continued swelling at the boarders of the lesion, and no sign of reepithelialization of the lesion. Diagnosis of Leishmania infection in these patients was confirmed by the identification of amastigotes using Giemsa staining of a smear from lesion aspirate tissue. All patients enrolled in the study were treated 1 month after completion of their last meglumine antimonate treatment. Patients were excluded from the study if any single lesion was 125 cm 2 in size or if their clinical status was complicated by pregnancy or any significant medical condition (e.g., AIDS, tuberculosis, bartonellosis, leprosy, sporotrichosis).
Initial evaluation and diagnosis of infection. A complete clinical history was obtained for all patients that included, age, sex, occupation, and characteristics of the lesion or lesions (e.g., number, type, size, localization, duration), details of previous treatment (e.g., duration, dosage, route of administration), and medical history. All patients had confirmed Leishmania infection at the time of the recruitment. The area of each lesion was measured by tracing the edges on a transparent plastic sheet, and a digital image of each lesion was made on the first day of treatment.
Treatment regimens. Before application of the imiquimod, each lesion was carefully cleaned with water and dried. Imiquimod was supplied in individual packets containing 250 mg of 5% (weight/volume) imiquimod cream. The content of 1 packet was applied to each lesion every other day for 20 days. The cream was spread over each lesion with a gloved finger and rubbed with a circular motion until the cream disappeared. The patients were instructed not to wash the treated area until the next day. In Peru, meglumine antimonate (Glucantime) is available in 5-mL ampules containing 1.5 g of meglumine antimonate, which corresponds to 425 mg of Sb 5ϩ . In combination with the imiquimod treatment, each patient received 20 mg of Sb 5ϩ per kg of body weight per day intramuscularly for 20 consecutive days. The administration of each dose was supervised by the study doctor. Side effects of meglumine antimonate were managed according to existing Peruvian Health Ministry guidelines. Assessment of response was performed daily by the same doctor. Plastic sheet and photographic images were obtained on days 5, 10, 15, and 20 of treatment. Followup data were available for all 12 patients at 4 months after treatment and for 10 of 12 patients at 6 months after treatment.
Outcome evaluation. The criteria used to define outcomes at the end of the 20-day treatment period were as follows. "Clinical cure" was defined as classical scar with disappearance of edema, induration, or other inflammatory signs at the end of treatment. "Clinical improvement" was defined as significant reduction in the size of the lesion at the end of treatment, assessed via the following scoring system: "M1," size of lesion or lesions decreased ∼50% with less inflammation (erythema, edema) and discrete reepithelialization; "M2," size of lesion or lesions decreased 50%-90%, with reduced inflammatory signs (erythema, edema); "M3," size of lesion or lesions decreased 190%, with complete reepithelialization and little or no evidence of inflammation; and "M4," closed lesion with little or no evidence of inflammation. "Treatment failure" was defined as no improvement, with the lesion active and unchanged or worsened compared with the lesion at the start of treatment. For patients with 11 lesion, the final response score was based on the lesion with the least improvement.
Adverse events. Before administration of each dose of meglumine antimonate or imiquimod, adverse events were recorded using a structured interview.
RESULTS

Patient characteristics.
A total of 12 patients with meglumine antimonate-resistant leishmaniasis were enrolled in the study; the clinical and demographic characteristics of the patients are outlined in table 1. The duration of presence of lesions before treatment varied from 3 to 20 months (mean duration ‫ע‬ SD, months). Twenty-one lesions were treated (mean num-7.1 ‫ע‬ 5.2 ber of lesions per patient ‫ע‬ SD, ), which were located 1.8 ‫ע‬ 0.9 on the face, leg, arm, ear, and hand. Nineteen lesions were of the ulcerative type, one of the verrucose type, and one of the nodular type (mean size, mm; table 1). 29.7 ϫ 17.3 Previous attempts to treat patients who did not respond to meglumine antimonate therapy with additional courses of iv meglumine antimonate at Cayetano Heredia Hospital in Lima have had limited success. Of 24 meglumine antimonate-resistant patients treated, only 6 showed considerable improvement and were eventually cured by 6 months after therapy. Therefore, the majority of patients who do not respond to an initial course of meglumine antimonate are not cured by a second course. Therefore, this provided our reference to examine the combination therapy of meglumine antimonate plus imiquimod, as detailed below.
Response to treatment. Each patient received 20 mg of Sb 5ϩ per kg of body weight per day intramuscularly in combination with imiquimod, which was applied to the lesion every other day for 20 consecutive days. All patients completed the combination therapy. Clinical response was analyzed by patient and by lesion at the end of the 20-day treatment period (table  2) . Six of 12 patients and 12 of 21 lesions were considered to be completely cured by the end of the 20-day treatment period. Significant clinical improvement was observed in the remaining 6 patients (3 patients were classified as M2, 2 as M3, and 1 as M4) and the remaining 9 lesions (5 lesions were classified as M2, 2 as M3, and 2 as M4; table 2; figures 1 and 2). None of the patients or individual lesions did not respond to the treatment. The 4 lesions that improved the least (M2) were found in the oldest (60 years old; 3 lesions) and youngest patients (18 months old; 1 lesion), raising the possibility that patients at the extremes of age may have a relative inability to generate T cell responses.
It is noteworthy that almost all of the lesions showed signs of reepithelization by day 10 of therapy ( figures 1 and 2 ). This is a remarkably fast response and is not characteristic of any previous treatments for cutaneous leishmaniasis. The single verrucose lesion was cured, and the nodular lesion achieved M4 status by day 20. It is also noteworthy that the largest lesion ( mm) was cured by day 20. There were no obvious 48 ϫ 23 differences in the response rate with regard to how the patients had received the previous treatment (intramuscularly vs. intravenously). Local side effects that were probably attributable to imiquimod were mild to moderate erythema (40%), edema (30%), and sensations of burning (10%). These side effects were primarily observed during the first 5 days of treatment, and they resolved progressively with the evolution of each lesion toward granulation tissue. These side effects were well tolerated, and none of the patients interrupted therapy.
At 2-4 months after the completion of therapy, all lesions that were partially healed at 20 days continued to improve or were entirely cured. It was possible to obtain further followup data on 10 of the 12 patients at у6 months after the completion of therapy. One of the 10 patients experienced a relapse ulcerative lesion on the face; the other 9 showed no evidence of relapse. Therefore, the cure rate of the combination therapy at the 6-month follow-up period is ∼90%.
DISCUSSION
Cutaneous leishmaniasis remains both a public health and a therapeutic challenge. Unfortunately, no ideal therapy for cutaneous leishmaniasis has been identified, and no universally accepted therapeutic regimen is available [1, 2] . Both primary and secondary treatment failures with drugs that contain antimony are increasing worldwide [5] . As a result, novel approaches to the treatment of leishmaniasis, including the use of drug combinations, are urgently required.
The major observation from this study is that therapy with imiquimod plus meglumine antimonate was effective in the treatment of cutaneous leishmaniasis patients who had not responded to a previous treatment with meglumine antimonate alone. Nine of 10 patients showed no sign of relapse at the 6-month follow-up period. This observation is particularly striking in light of the increasing resistance to pentavalent antimony worldwide [2, 5] and the poor cure rate (!20%) with a second course of meglumine antimonate in patients who previously had not responded to meglumine antimonate treatment. The observations we report are also consistent with the findings of another study of ours that showed that imiquimod was effective in the treatment of cutaneous leishmaniasis in mice [9] .
It is noteworthy that our first attempt to use imiquimod for the primary treatment of cutaneous leishmaniasis was of limited success. Ten patients with cutaneous leishmaniasis who had never been treated before were recruited in an open-label trial of imiquimod alone (authors' unpublished results). Only 4 of 10 patients completed the 20-day treatment course, and only 1 of these 4 patients showed significant improvement.
It is possible that there is a synergistic effect between imiquimod and meglumine antimonate because it has been recently reported that endogenous IFN-g is involved in the leishmanicidal response to pentavalent antimony [11] ; we have shown that imiquimod acts similarly to IFN-g to induce nitric oxide release from macrophages [9] . Future studies should now investigate the use of combined imiquimod and meglumine antimonate therapy for the primary treatment of cutaneous leishmaniasis to determine if this could reduce the amount of meglumine antimonate needed, reduce the time of treatment, or reduce the incidence of drug resistance to pentavalent antimony therapy. Reducing the occurrence of drug resistance or the amount of pentavalent antimony in the treatment of cutaneous leishmaniasis would indeed represent a significant advance in the treatment of this disease.
Two additional interesting observations in this study were the rapidity with which these "refractory" lesions resolved and the absence of serious local adverse reactions to the imiquimod used in combination with meglumine antimonate. The majority (11 of 21) of these chronic lesions had evidence of reepithelialization only 10 days after initiation of combined therapy, which raises the possibility that imiquimod stimulates the production or release of local mediators that enhance wound healing. This is consistent with our observation that imidazoquinolines are able to induce the expression of the plasminogen activator inhibitor gene in macrophages, which is involved in healing of inflammatory lesions [10] .
It is also interesting that there was considerable variability in the speed of response. For example, the largest lesion (48 ϫ 23 mm) had evidence of active reepithelization by day 10 and was completely cured at day 20. In contrast, the smallest lesion had a later onset of reepithelization and only achieved M2 status by day 20. It is possible that the variable rates of clinical improvement reflect differences in host factors that could not be identified in this study. Future studies will be required to examine the mechanism or mechanisms by which combined imiquimod and meglumine antimonate work synergistically and to establish optimal dosing and duration of therapy.
The results of this open-label study suggest that combined imiquimod and meglumine antimonate should be considered for patients with cutaneous leishmaniasis who have failed to respond to initial therapy with meglumine antimonate alone.
